Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.63 +5.14%

+$0.45 today

Market cap
$53.90M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.01M

Average 0.05M

XLO Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Xilio Therapeutics, Inc.NASDAQ: XLO

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $26.42M rose 57.4% year over year, ahead of the +20.9% change in trailing-twelve-month operating expenses. Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at -1.9% a year.

Context

  • Operating expenses amounted to 192.4% of revenue in FY2025, down 862.5 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +57.4% holds above the trailing-twelve-month pace of +20.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$26.42M+3.5% QoQ
Last fiscal yearDec 2025
$84.21M+25.8% YoY
LTMMar 2026
$80.05M+20.9% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57.4%——
1 year+25.8%——
3-year CAGR-1.9%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
84.21M USD
Year-over-year change
+25.8%
4-year CAGR
+3.4%

Operating Expenses vs competitors

How XLO compares with its peers on the latest reported figures

  • XLO's LTM Mar 2026 operating expenses of $80.05M is the highest of the 4 companies compared; the peer median is $28.96M.
  • Its year-over-year change of +20.9% is the highest of 4, against a peer median of -18.0%.
  • Operating expenses amounts to 149.7% of revenue for XLO, versus a peer median of 73.9%.
XLO Competitors Peer median
Operating Expenses for XLO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XLOXilio Therapeutics, Inc.LTM Mar 2026$80.05M +20.9%-1.9%149.7%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$61.36M -12.1%+27.8%—
PDSBPDS Biotechnology CorporationLTM Mar 2026$28.96M -18.0%-8.9%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$25.93M -40.9%+1.1%73.9%
Peer median (excluding XLO) $28.96M-18.0%+1.1%73.9%

Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0006.34M43.77M
Cost of Revenue1.5M0001.54M
Gross Profit(1.5M)006.34M42.23M
Gross Margin———100.0%96.5%
Research & Development51.19M59.2M52.14M41.21M56.04M
Selling, General & Admin22.36M29.95M27M24.78M29.71M
Operating Expenses73.55M89.15M79.13M66.93M84.21M
Depreciation & Amortization1.5M1.85M1.9M1.64M1.54M
EBITDA(73.7M)(86.38M)(74.5M)(58M)(33.5M)
EBITDA Margin———-914.3%-76.5%
Operating Income(75.04M)(89.15M)(79.13M)(60.58M)(41.98M)
Operating Margin———-954.9%-95.9%
Interest Income6000003.4M
Interest Expense600K00100K0
Other Income / Expenses(756K)927K2.73M2.34M6.95M
Income Before Tax(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Pre-Tax Margin———-918.0%-80.1%
Income Tax Expense00000
Net Income(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Net Margin———-918.0%-80.1%
EPS (Basic)(189.28)(45.08)(38.92)(15.26)(4.19)
EPS (Diluted)(189.28)(45.08)(38.92)(15.26)(4.19)
Weighted Avg Shares400.45K1.96M1.96M3.82M83.59M
Weighted Avg Shares (Diluted)400.45K1.96M1.96M3.82M83.59M

Xilio Therapeutics, Inc.

NASDAQ:XLO

Intrinsic Alpha fair value

Locked

Current Price

$7.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.